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MaBecause nonpharmacological interventions likely alter the risks and beneﬁts associated with rhythm control, this paper
reviews the role of current rhythm control strategies in atrial ﬁbrillation. This report also focuses on the speciﬁc limi-
tations of pharmacological interventions and the utility of percutaneous ablation in this growing population of patients
with concomitant atrial ﬁbrillation and heart failure. (J Am Coll Cardiol 2014;64:710–21) © 2014 by the American College
of Cardiology Foundation.A trial ﬁbrillation (AF) and heart failure (HF)loom as 2 burgeoning public health problemsthat impair quality of life (QOL) and reduce
longevity (1,2). Both can beget and/or accentuate
the severity of the other, and synergistically confer
worse outcomes when compared with patients with
either condition alone (3). Despite extensive compar-
isons between rate and rhythm control for AF, neither
strategy has proven to be superior in patients with
(4) or without (5) HF. However, these trials strictly
tested medical therapy and were limited by substan-
tial crossover, suboptimal therapeutic efﬁcacy, and
adverse effects of pharmacological therapy (4–6).
EPIDEMIOLOGY
AF is the most common cardiac arrhythmia and af-
fects more than 33 million individuals across the
globe. Due in part to the aging population, each year
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women (10,11). Importantly, this arrhythmia carries
risk for signiﬁcant morbidity, including thromboem-
bolic stroke, tachycardia-induced cardiomyopathy,
and debilitating symptoms. AF not only impairs QOL
(2), it also is associated with diminished survival. The
Framingham Heart Study reported 10-year death
rates in individuals with AF at 61% and 58% in men
and women, respectively, compared with 30% and
21% in men and women without AF (1).
HF, a diagnosis that encompasses those with both
preserved and reduced ejection fractions (EF), is also
increasingly prevalent (12). As the care for coronary
artery disease and acute coronary syndromes im-
proves, the incidence of ischemic cardiomyopathy
has increased accordingly. Population studies suggest
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AB BR EV I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation
EF = ejection fraction
FIRM = focal impulse and rotor
modulation
HF = heart failure
HFpEF = heart failure with
preserved ejection fraction
LV = left ventricular
LVEF = left ventricular
ejection fraction
NYHA = New York Heart
Association
PVI = pulmonary vein isolation
QOL = quality of life
RAAS = renin-angiotensin-
aldosterone system
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711decade (12,13). Irrespective of etiology, a diagnosis of
HF carries a poor prognosis, with an estimated 5-year
survival of 25% to 38% (13).
SYMPTOM BURDEN, QUALITY OF LIFE,
AND STROKE RISK
QOL is impaired in patients with AF and HF, both
alone and in concert (2), with the primary drivers of
this deterioration of QOL being one’s perception of
health, physical symptoms, and ﬁnancial burden. A
QOL analysis of the AFFIRM (Atrial Fibrillation
Follow-up Investigation of Rhythm Management)
trial demonstrated improved QOL in those treated
with either rate or rhythm control therapies (14). The
failure of rhythm control to yield superior QOL
compared with rate control may have been due to the
limited effectiveness or adverse effects of antiar-
rhythmic therapy despite the advantages of sinus
rhythm.
Similar results were reported in the AF-CHF (Atrial
Fibrillation and Congestive Heart Failure) trial (15),
where both rate and rhythm control improved
symptoms, but sinus rhythm had the added beneﬁt
of being associated with improved New York Heart
Association functional class and QOL. Importantly,
impaired QOL in patients with AF and HF appears
to predict both hospitalization and mortality (16),
thus highlighting the importance of treatment and,
potentially, the restoration of sinus rhythm.
AF increases stroke risk several fold (17), and AF-
related strokes are associated with signiﬁcantly
reduced QOL, disability, and mortality (18). Not sur-
prisingly, an analysis of the AFFIRM study failed to
show a signiﬁcant difference in stroke risk between
the rate and rhythm control arms, although a post-
hoc analysis suggested that the presence of AF was
associated with an increased risk of ischemic stroke,
whereas sinus rhythm and systemic anticoagulation
were associated with a lower risk of stroke (19).
Subsequent studies have continued to raise the
hypothesis that the reduction and/or elimination of
AF decreases stroke risk. Recently, a retrospective
observational analysis of age- and sex-matched pa-
tients suggested that catheter ablation of AF was
associated with a lower risk of incident stroke (20).
Across all CHADS2 proﬁles, patients who underwent
ablation demonstrated lower long-term risk of stroke
than those with AF who did not undergo ablation. It
should be noted that this study did not fully adjust
for clinically important covariates that could inﬂu-
ence stroke risk. Additionally, the average EF in the
ablation group was 58%, and data regarding mainte-
nance of sinus rhythm in follow-up were notavailable. Nevertheless, these data raise the
possibility that successful ablation of AF may
signiﬁcantly modify long-term stroke risk in
patients with AF. Other studies also have
reported very low rates of thromboembolic
events after successful AF ablation (21,22),
albeit in populations with relatively low
CHA2DS2-VASc scores. Whether or not AF
ablation can reduce the risk of stroke in pa-
tients with and without HF will require large
randomized studies such as the CABANA
(Catheter Ablation vs Antiarrhythmic Drug
Therapy for Atrial Fibrillation), RAFT AF (A
Randomized Ablation-based Atrial Fibrilla-
tion Rhythm Control Versus Rate Control
Trial in Patients With Heart Failure and
High Burden Atrial Fibrillation), and the
CASTLE-AF (Catheter Ablation Versus Stan-
dard Conventional Treatment in Patients
With Left Ventricular Dysfunction and Atrial Fibril-
lation) trials.
SHARED MECHANISMS IN AF AND HF
As heterogeneous syndromes, AF and HF often
represent the culmination of many adverse physio-
logical conditions, including common cardiovascular
disorders such as hypertension and coronary
ischemia. Indeed, AF and HF may be considered
“chamber-speciﬁc expressions” of global myocardial
damage. That is, analogous cellular abnormalities in
the atria and ventricles, resulting from diverse un-
derlying pathologies and genetic predisposition, may
manifest as electrical abnormalities and ﬁbrillation in
the atria and pump failure with elevated risk of
ﬁbrillation in the ventricles—although the reciprocals
are also observed (23). Increasingly appreciated
morbid conditions/risk factors including obesity, to-
bacco use, hypertension, diabetes, kidney disease,
sleep apnea, and coronary disease are primary drivers
of this process. Not unexpectedly, multiple large co-
horts have described these comorbidities and envi-
ronmental inﬂuences as independent risk factors for
both AF and HF. Figure 1 illustrates this shared rela-
tionship between diverse conditions and the patho-
genesis of AF and HF.
In addition to their shared underlying risk factors,
AF and HF also are independent risk factors for one
another (3,24). Among persons with HF, the preva-
lence of AF ranges between 15% and 50% (Fig. 2).
Although it remains uncertain whether AF indepen-
dently portends increased mortality in patients
with HF, it is an independent predictor of worsening
left ventricular (LV) function and impaired QOL
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FIGURE 1 Hazard Ratio of Incident AF and HF According to Shared Risk Factors
Adjusted hazard ratios (95% conﬁdence limits) of atrial ﬁbrillation (AF) (left) and heart failure (HF) (right) according to 7 shared risk factors.
These data were gathered through studies of various cohorts. If overall cohort data were unavailable or not reported, results from white and/or
male patients (both the largest subgroups) were reported. References: a ¼ (91); b ¼ (92); c ¼ (93); d ¼ (94); e ¼ (95); f ¼ (96); g ¼ (97);
h ¼ (98); i ¼ (99); j ¼ (100); k ¼ (101).
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712(1,24–26). In a retrospective analysis of the SOLVD
(Studies Of Left Ventricular Dysfunction) trial, Dries
et al. (25) found that AF was signiﬁcantly associated
with increased mortality in patients with AF versus
sinus rhythm who had underlying asymptomatic or
symptomatic LV dysfunction. Numerous studies
corroborate the association of poorer overall prog-
nosis in patients with AF or HF and the development
of the other (3,25,27,28).
ATRIAL FUNCTION AND
CARDIAC PERFORMANCE
As depicted in the Central Illustration, much effort
has been spent in understanding the causal pro-
cesses and shared mechanisms between AF and HF.
Though multifactorial, key organ-level and subcel-
lular pathophysiologic processes have been eluci-
dated. There exist numerous mechanisms through
which a diseased ventricle may promote atrial
tachyarrhythmias. Hemodynamically, elevated ven-
tricular ﬁlling pressures, functional valvular regurgi-
tation, and renin-angiotensin-aldosterone system
(RAAS)-induced volume retention promote left atrial
dilation. Mechanically, stretching of the myocardium
enhances pulmonary venous ectopy (the most com-
mon AF trigger) (29), promotes re-entry, and slowsconduction; all of these actions promote the onset of
AF (30–33). Neurohormonally, RAAS activation and
increased circulating levels of angiotensin II lead to
atrial ﬁbrosis and anisotropy (34). Myocardial ﬁbrosis
heralds electrical dysfunction, including slowed and
heterogenous conduction times that facilitate wave
break. These changes expedite the development and
persistence of additional AF triggers and AF perpet-
uators, including electrical spiral waves (rotors) and
focal sources (35). Finally, cellular calcium dysregu-
lation occurs in HF as a result of altered myocardial
contraction function and modiﬁed calcium channel
concentration, but has important electrophysiolog-
ical consequences as well. Calcium overload likely
facilitates abnormal action potential durations within
the atria that have been associated with both
increased AF triggers as well as enablement of re-
entry (36).
Atrial contraction plays an important role in ven-
tricular ﬁlling. Loss of atrial systole can lead to as
much as a 25% reduction in cardiac output, although
this reduction is exaggerated when ventricular
compliance is limited (37). Additionally, irregularity
of ventricular cycle lengths (regardless of atrial
function or ventricular rate) reduces cardiac output
(38). Uncontrolled, irregular, and rapid ventricular
conduction in the setting of inefﬁcient and impaired
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FIGURE 2 Prevalence of AF in Patients Enrolled in HF Studies
The bars represent percentages of patients with HF who had concomitant AF at enrollment
in 10 clinical trials. Studies include SOLVD (Studies of Left Ventricular Dysfunction) (25);
SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) (102); DEFINITE (Deﬁbrillators in
Non-Ischemic Cardiomyopathy Treatment Evaluation) (103); CHARM (Candesartan in Heart
Failure: Assessment of Reduction in Mortality) (104); I-PRESERVE (Irbesartan in Patients
with Heart Failure and Preserved Ejection Fraction) (105); A-HeFT (African-American Heart
Failure Trial) (106); EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and
Survival Study in Heart Failure) (107); ANDROMEDA (Increased Mortality After Dronedar-
one Therapy for Severe Heart Failure) (108); and CONSENSUS (Cooperative North
Scandinavian Enalapril Survival Study) (109). Other abbreviations as in Figure 1.
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713cardiac output can lead to ventricular dysfunction
and tachycardia-mediated cardiomyopathy (37,39).
However, immediately after cardioversion, increases
in stroke volume and left ventricular ejection fraction
(LVEF) are observed, despite the absence of demon-
strable improvement in contractility (40). These
physiological observations serve as the primary
rationale behind strategies to prevent recurrent
arrhythmia and maintain sinus rhythm in AF patients
with and without underlying cardiovascular disease.
PHARMACOLOGICAL RHYTHM CONTROL
CONSIDERATIONS
Multiple studies have compared pharmacological rate
and rhythm strategies but have failed to identify a
superior therapy, a ﬁnding that extends to patients
with HF (4,41). Nevertheless, these trials actually
tested medical therapeutic strategies and did not
truly compare rate versus rhythm control because of
substantial crossovers between treatment arms; spe-
ciﬁcally, patients receiving antiarrhythmic therapy
were often in AF, whereas patients receiving rate
control therapy were often in sinus rhythm. Finally,
these studies were limited, not only by suboptimal
efﬁcacy, but also by the adverse effects of pharma-
cological therapy.
Antiarrhythmic drug therapy is indicated as ﬁrst-
line therapy for AF that remains symptomatic despite
adequate rate control (42). Unfortunately, many
antiarrhythmic drugs are contraindicated in patients
with structural heart disease, and those that are
not have signiﬁcant side effects and/or toxicities
(42). Amiodarone and dofetilide are the lone
guideline-recommended antiarrhythmic medications
for patients with symptomatic HF or signiﬁcant LV
dysfunction, yet they have signiﬁcant adverse effects
and drug–drug interactions (43). Amiodarone, for
example, carries the risk of pulmonary, hepatic, and
thyroid toxicity (44). Despite its potency, recurrence
rates in patients with AF and HF are 50% or greater at
1 year (45). Equally concerning, a chief risk of dofe-
tilide therapy is that it prolongs the QT interval and
can lead to torsades in 0.8% to 3.3% of those treated.
To mitigate these risks, initiation of dofetilide re-
quires a 3-day hospitalization for careful monitoring.
Moreover, dofetilide is renally cleared and must be
adjusted (if used at all) in patients with renal
dysfunction, which commonly accompanies HF (44).
Pre-clinical development of AF therapies has
increased signiﬁcantly, and there are several novel
therapeutic modalities on the horizon. Furthermore,
the development of biomarkers for AF disease
severity and response to treatment may alsotransform our approach to AF care. These advances
have highlighted the need for a future personalized
approach to AF management (46). Well-known for its
antianginal properties and limited side-effect proﬁle,
ranolazine is being studied increasingly in HF and
AF. A late sodium-channel antagonist, ranolazine
promotes myocardial relaxation by decreasing intra-
cellular calcium and has been shown to reduce atrial
and ventricular arrhythmias (47,48). It has been re-
ported as an effective synergistic adjunct to amio-
darone for AF (49,50) and is currently being studied
as a lone antiarrhythmic drug and in ﬁxed-dose
combination with dronedarone (51). Budiodarone,
an amiodarone analogue with a shorter half-life and
alternative metabolism, has been investigated for AF
rhythm control with the hope of producing fewer side
effects (52); to date, studies aimed primarily at an HF
population do not exist. Genotype-directed therapy
for AF is another promising line of investigation
and another possible means of personalizing AF
treatment. Beta-blocker therapy tailored to beta-
adrenergic receptor genotype is 1 such possibility.
Patients with HF who are b₁ adrenergic receptor 389
Arg homozygotes exhibit a signiﬁcant reduction in
new-onset AF when treated with bucindolol (vs.
placebo) when compared with b₁389 Gly carriers
(hazard ratio: 0.26, 95% conﬁdence interval: 0.12 to
0.57 vs. hazard ratio: 1.01, 95% conﬁdence interval:
CENTRAL ILLUSTRATION The Physiological Relationship Between
Atrial Fibrillation and Heart Failure
*Action potential duration heterogeneity includes spatial and temporal nonuniformities
(36). **This mechanistic hypothesis has fallen out of favor with recent evidence (33).
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7140.56 to 1.84; p for interaction ¼ 0.008) (53). The
ongoing GENETIC-AF (Genetically Targeted Therapy
for the Prevention of Symptomatic Atrial Fibrillation
in Patients With Heart Failure) clinical trial will test
the hypothesis that genotype-directed bucindolol
therapy is superior to metoprolol for the prevention
of symptomatic AF in patients with HF.
CATHETER ABLATION FOR RHYTHM
AND SYMPTOM CONTROL
ABLATION TECHNIQUE. Given the limitations of
current antiarrhythmic drug therapy, clinicians have
shown great interest in the use of nonpharmacological
rhythm control interventions in patients with AF and
HF. The role of catheter ablation is not simply to
restore and maintain sinus rhythm, but more impor-
tantly, to ameliorate symptoms and improve QOL. The
percutaneous technique, at a minimum, employs
circumferential ablation and hence electrical isolation
of the pulmonary veins and their connection to atrial
myocardium. Additional ablation, such as linear abla-
tion and/or focal ablations of areas with evidence
of scar, fractionation, or rotor-perpetuation, may be
employed, too, depending upon the type of AF anddegree of left atrial disease (Fig. 3) (54–56). Ablation of
complex fractionated atrial electrograms as an adjunct
to pulmonary vein isolation (PVI) has been demon-
strated to increase freedom from AF compared with
PVI alone (55,57). Several investigators have demon-
strated that the focal impulse and rotor modulation
(FIRM) technique, distinct from PVI, can successfully
identify ablative targets, called rotors, and terminate
or slow AF and improve arrhythmia-free outcomes
compared with conventional ablation alone (56,57). As
our understanding of the mechanisms behind AF
initiation and propagation continues to advance, du-
rable targets for novel therapies are evolving in tan-
dem (58).
ABLATION VERSUS ANTIARRHYTHMIC DRUG THERAPY.
Although the efﬁcacy of catheter ablation varies
according to the underlying severity and duration of
AF, multiple studies have established its superiority
in those patients with recurrent AF despite antiar-
rhythmic drug therapy (59,60). Meta-analyses of
clinical trials have concluded PVI to be superior to
antiarrhythmic drug therapy as a second-line therapy
for maintaining sinus rhythm, improving physical
functioning, and potentially, reducing readmission
rates for patients with symptomatic AF (60,61).
Initial studies comparing antiarrhythmic drug ther-
apy versus catheter ablation as initial therapy in
treatment-naive patients with paroxysmal AF have
revealed conﬂicting results (62,63); hence, catheter
ablation is not typically employed as ﬁrst-line ther-
apy. However, a recent clinical trial demonstrated a
signiﬁcant attributable beneﬁt of catheter ablation
compared with antiarrhythmic therapy as ﬁrst-line
therapy for preventing recurrent atrial tachyarrhyth-
mias at 2 years (64). Notably, these studies were not
primarily performed in patients with HF, and many of
the antiarrhythmic medications used are contra-
indicated in patients with HF. To date, there are no
studies investigating catheter ablation as ﬁrst-line
treatment for AF in HF patients. Although some trials
include freedom from antiarrhythmic drugs as a ther-
apeutic endpoint of catheter ablation, it should be
noted that the 2 interventions may be synergistic or
even necessary to ameliorate AF-associated symptoms
and potentially restore sinus rhythm.
EFFICACY AND OUTCOMES FOR CATHETER
ABLATION. Importantly, studies citing the highest
success rates of catheter ablation are composed pri-
marily of middle-aged men with few comorbidities
and often included repeat or redo ablation pro-
cedures. A smaller number of trials have been per-
formed in dedicated cohorts with AF and concomitant
HF. Table 1 details and reviews the available
FIGURE 3 Approaches to Catheter Ablation in AF and HF
CFAE ¼ complex fractionated atrial electrogram; PV ¼ pulmonary vein; PVI ¼ pulmonary
vein isolation; other abbreviations as in Figure 1.
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715observational and randomized studies of catheter
ablation in this patient population.
Initial studies sought to identify success/failure
rates of catheter ablation in patients with and without
HF. At 15-month follow-up, Chen et al. (65) reported
13% of patients with normal EF developed recurrent
AF versus 27% in those with reduced EF (p ¼ 0.03),
despite similar risk proﬁles. However, after including
outcomes following a second procedure, 96% of pa-
tients with reduced EF remained in sinus rhythm
during follow-up without antiarrhythmic drug ther-
apy. Importantly, both groups experienced signiﬁcant
improvement in QOL. Gentlesk et al. (66) reported a
somewhat similar experience in a 2007 study, which
found no difference in success rates of catheter abla-
tion in patients with and without LV dysfunction
(86% vs. 87%), though patients with reduced EF more
often required repeat ablation. In patients with LV
dysfunction, maintenance of sinus rhythm resulted in
an average absolute increase in EF of 14%. These
studies highlight the need for randomized trials to
better evaluate the role and efﬁcacy of ablative
therapy.
An alternative procedure, atrioventricular node
ablation with pacing, has shown efﬁcacy in patients
with refractory AF and HF (67). To compare the ex-
tremes of rate and rhythm control strategies, the
PABA-CHF (Pulmonary Vein Antrum Isolation versus
AV Node Ablation with Bi-Ventricular Pacing for
Treatment of Atrial Fibrillation in Patients with
Congestive Heart Failure) study randomized 41 pa-
tients to atrioventricular node ablation and sub-
sequent biventricular pacing versus PVI (68). At
6-month follow-up, the PVI group had 88% AF-free
survival and an absolute increase in LVEF of 8%
versus no change in the biventricular pacing/nodal
ablation group (p < 0.001). Functional capacity was
enhanced with PVI based on signiﬁcant improve-
ments in both the 6-min walk test and QOL. The out-
comes suggest that atrioventricular node ablation and
pacing was inferior to PVI, but the study did not
evaluate the less invasive, more common strategy of
pharmacological rate control.
Several clinical trials have since compared phar-
macological rate control with AF ablation (PVI 
focal substrate ablation). The ﬁrst of these trials
demonstrated a nonsigniﬁcant trend toward LVEF
improvement in the ablation group, without signiﬁ-
cant between-group differences in QOL or exercise
capacity (69). Limitations of the study included only
50% maintenance of sinus rhythm in the ablation
group and a higher-than-expected maintenance of
sinus rhythm in the rate control arm. Two trials have
since reported signiﬁcant improvement in QOL andexercise capacity after ablation compared with usual
rate control therapies (70,71). Speciﬁcally, the ARC-
HF (A Randomised Trial to Assess Catheter Abla-
tion Versus Rate Control in the Management of
Persistent Atrial Fibrillation in Chronic Heart Fail-
ure) investigators (71) reported a trend toward
EF improvement in the ablation group at 12 months,
whereas the CAMTAF (Catheter Ablation Versus
Medical Treatment of AF in Heart Failure) trial (70)
found signiﬁcant improvement at 6 months. The
aforementioned studies primarily enrolled and
aimed to evaluate patients with HF and reduced EF;
the CAMTAF trial was notable in that the inclusion
EF cutoff was #50% compared with the more typical
35% cutoff in the other trials. However, the average
LVEF in the CAMTAF trial was still signiﬁcantly
reduced at 32% pre-intervention. This is notable
because there remains a paucity of data surrounding
AF therapies in the setting of heart failure with
preserved ejection fraction (HFpEF). It stands to
reason, as in HF with reduced EF, that patients with
HFpEF would also beneﬁt from atrioventricular
synchrony. Emerging data from a single-center study
indicates that catheter ablation success rates in pa-
tients with HFpEF are similar to those without
ventricular dysfunction and resultant sinus rhythm
is associated with improved systolic and diastolic
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716function measures (E0/E and LV strain) (72). Addi-
tionally, there were no major complications in the
ensuing 36-month follow-up period.
Thus, the available data suggest that catheter
ablation leads to maintenance of sinus rhythm in a
substantial portion of patients with AF and HF.
Furthermore, and perhaps more importantly, those
undergoing PVI appear to have improved QOL and
better neurohormonal proﬁles. As a result, guideline
recommendations suggest that catheter ablation may
be reasonable to treat symptomatic paroxysmal AF in
patients with mild LV dysfunction (Class I, Level of
Evidence: A) or signiﬁcant LV dysfunction (Class IIb,
Level of Evidence: A) (43). However, there is a need for
larger randomized trials to adequately assess the
safety and efﬁcacy of ablation for achieving sustained
sinus rhythm and improving functional capacity.
Similarly, larger, multicenter trials will help explore
the generalizability of results obtained from smaller
studies. The much-anticipated RAFT AF (A Random-
ized Ablation-based Atrial Fibrillation Rhythm Control
Versus Rate Control Trial in PatientsWithHeart Failure
and High Burden Atrial Fibrillation) and CASTLE-AF
(Catheter Ablation Versus Standard Conventional
Treatment in Patients With Left Ventricular Dysfunc-
tion and Atrial Fibrillation) studies should help pro-
vide answers to these questions, with earliest results
anticipated in 2016.
PROCEDURAL SAFETY. Although catheter ablation in
patients with AF and HF has led to promising success
rates in early studies, there remains room for im-
provement. Additionally, as with any percutaneous
intervention, we see small but signiﬁcant procedural
risks. One meta-analysis of studies of catheter abla-
tion in patients with LV systolic dysfunction esti-
mated a 4.8% overall major adverse event rate, which
included death, stroke, pulmonary vein stenosis,
pericardial tamponade, and signiﬁcant bleeding;
there were no signiﬁcant differences in adverse
events between patients with or without reduced EF
(73). The procedural risks also need to be considered
in light of the fact that more patients with HF will
require a repeat procedure compared with those
without HF. It also stands to reason that procedural
complication rates may be higher at institutions with
lower procedural volumes.
EMERGING TECHNOLOGIES AND
FUTURE DIRECTIONS
Ongoing clinical trials will help answer several
important questions surrounding the safety and ef-
ﬁcacy of catheter ablation of AF in patients with HF.
In the meantime, numerous important questions
TABLE 2 Key Questions Speciﬁc to Catheter Ablation of AF in
Patients With HF
1. Does catheter ablation improve mortality compared with a pharmacological rate
control strategy?
2. Is the efﬁcacy of catheter ablation for AF dependent on the etiology of HF
(ischemic vs. nonischemic)?
3. Are post-ablative improvements in functional capacity and quality of life
preserved beyond 1 year?
4. Does catheter ablation reduce HF hospitalization at 1-year and longer follow-up?
5. Is catheter ablation cost effective in patients with HF?
6. Does catheter ablation improve freedom from antiarrhythmic drugs in long-term
follow-up?
7. Is catheter ablation a viable ﬁrst-line treatment of AF in patients with HF?
8. Does focal impulse rotor modulation improve maintenance of sinus rhythm over
and above pulmonary vein isolation?
9. Should linear ablation be performed during a ﬁrst catheter ablation procedure in
all patients with HF (preserved and reduced EF)?
10. Should termination of AF be a goal of ablation in patients with HF and persistent
forms of AF?
11. Does catheter ablation improve long-term renal function in patients with HF?
12. Does renal denervation improve maintenance of sinus rhythm in hypertensive
HF patients undergoing catheter ablation?
Abbreviations as in Table 1.
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717merit continued investigation (Table 2). Chief among
these questions is whether or not the promising re-
sults achieved in smaller clinical trials will be
observed in larger clinical studies. These larger
studies will help provide needed data on the gener-
alizability and effectiveness of catheter ablation.
Long-term outcome studies are needed to help un-
derstand whether the beneﬁts observed at 1 year after
ablation are maintained in longer follow-up. This is a
particularly important concern given the high risk for
clinical progression and repeat hospitalization in
patients with symptomatic HF. The impact of cath-
eter ablation on HF hospitalization may have signif-
icant implications for its cost effectiveness, because
hospitalizations for HF represent a major healthcare
expenditure in many healthcare systems across the
globe (12).
Beyond outcomes, important unanswered ques-
tions remain regarding the optimal technique for
catheter ablation in patients with both paroxysmal
and persistent AF. In particular, AF that is persistent
and associated with HF has no standard acute pro-
cedural endpoints beyond PVI. Neither the optimal
lesion set nor the appropriate endpoint of ablation
has been determined. Some investigators advocate
that termination of AF during ablation is an impor-
tant endpoint because of an apparent association
with freedom from AF (74–76). However, not all
studies support termination of AF during ablation
as an important endpoint (77), leading other in-
vestigators to prefer empiric lesion sets (78). The
more longstanding an episode of AF, particularly
when associated with structural heart disease or HF,
the more complex the decision making. A limitation
of current ablation procedures (and associated lesion
sets) is the poor durability of endocardial lesions and
conduction block. Emerging ablation technologies
such as annotation algorithms based upon catheter
stability and impedance drops (79), next-generation
cryoballoon catheters (80), and contact-force sensing
(81) offer the promise of more robust and durable
lesion sets.
Should adjunctive ablation be performed in all
patients with HF, only those with reduced EF, or only
those with persistent AF (regardless of HF status)?
The risk of recurrence is higher in patients with HF,
yet the risk of proarrhythmia is likely to be increased
as well. Finally, the role of newer mechanistic ap-
proaches, including FIRM and renal vein denerva-
tion, requires study. FIRM-guided ablation leads to
improved freedom for AF when compared with PVI
alone (82.4% vs. 44.9%; p < 0.0001) (57). These
techniques have shown great promise in general AF
ablation populations, but outside of promising smallsubstudies in HF patients (82), their beneﬁts to the
wider AF population remain to be determined.
It is important to emphasize that the development
of new technologies and techniques and their appli-
cation to rhythm control in AF and HF require further
and iterative evaluation, including any means of
identifying critical substrate. For example, if the
durability of PVI improves, many of the previous
studies that look at adjunctive therapy may no longer
be valid, and these strategies may need to be re-
evaluated.
HYBRID AND SURGICAL ABLATION
APPROACHES
Beyond pharmacological and catheter ablation
approaches, there exist other methods of rhythm con-
trol in order to attenuate AF. The hybrid endocardial–
epicardial ablation, or “convergent” procedure, was
designed to be less invasive and avoid the need for
chest incisions, lung deﬂation, and heart dissection
(83). A transdiaphragmatic endoscopic approach is
utilized to make gapped epicardial lesions, which are
later connected via percutaneous mapping and endo-
cardial ablation. Two prospective nonrandomized
studies have demonstrated the general safety and
efﬁcacy of this procedure for treatment of drug-
refractory AF (83,84), but only 16% of patients in
these studies had comorbid HF, and the average LVEF
was 55% to 58%. Gehi et al. (85) found similar results in
a cohort of 101 patients, 30% of which had comorbid
HF with an average pre-procedural EF of 50%.
Trulock et al. J A C C V O L . 6 4 , N O . 7 , 2 0 1 4
Rhythm Control in AF With HF A U G U S T 1 9 , 2 0 1 4 : 7 1 0 – 2 1
718Arrhythmia-free survival was 66% at 12 months after a
single procedure and 71% after repeat ablation with a
major periprocedural complication rate of 6%.
The Cox-Maze III procedure is the surgical stan-
dard for medical-refractory AF. It is most often per-
formed in the setting of concomitant valve surgery
and/or revascularization procedures, and is associ-
ated with decreased AF burden without signiﬁcant
complications when compared with usual surgical
care (86). The traditional cut-and-sew approach
serves as the gold standard for conduction block
because it provides deﬁnitive transmural injury to
cardiac tissue, whereas catheter ablation and hybrid
approaches create endocardial and endocardial/
epicardial lesions, respectively. Overall, the strength
of evidence for surgical maze procedures versus
usual surgical care, in regard to restoration and
maintenance of sinus rhythm, is reasonable yet
insufﬁcient when considering post-procedural HF
symptoms and QOL (87). There is limited evidence
when comparing the cut-and-sew approach to other
surgical maze modalities (radiofrequency, micro-
wave, or cryothermy), though retrospective data are
suggestive of cut and sew being superior in achieving
freedom from AF (88,89). Few data are available
describing outcomes in patients with LV dysfunction
and/or HF who undergo surgical ablation. In a series
of 42 patients with AF, a LVEF <40% and symp-
tomatic HF undergoing cardiac surgery with
concomitant Cox-Maze III/IV procedures, 86% of
patients were in sinus rhythm at a median of
6 months (90). The average improvement in LVEFwas 15%, and perioperative mortality was 2%. These
data suggest that surgical ablation in patients with
HF and signiﬁcant LV dysfunction may be possible
without signiﬁcant added operative risk. Similar to
other rhythm control interventions in the AF/HF
population, additional studies are warranted.
CONCLUSIONS
In this ever-expanding population of patients with
concomitant AF and HF, it is apparent that sinus
rhythm provides improved ventricular function,
physical function, and overall QOL. Catheter ablation
offers a superior approach to achieving sinus rhythm
compared with antiarrhythmic drug therapy alone,
especially when considering the few available agents
for use in patients with HF. Although there are
limited studies reporting on major cardiovascular
outcomes following catheter ablation in patients with
HF, recent trials note improvement in prognostic
surrogates for HF outcomes as well as QOL. Future
studies, including large randomized trials, will help
delineate the utility of this procedure in reducing
morbidity and, perhaps, mortality in patients with
concomitant AF and HF.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Jonathan P. Piccini, Electrophysiology Section, Duke
Center for Atrial Fibrillation, Duke University Medical
Center, Duke Clinical Research Institute, PO Box
17969, Durham, North Carolina 27710. E-mail:
jonathan.piccini@duke.edu.RE F E RENCE S1. Benjamin EJ, Wolf PA, D’Agostino RB,
Silbershatz H, Kannel WB, Levy D. Impact of atrial
ﬁbrillation on the risk of death: the Framingham
Heart Study. Circulation 1998;98:946–52.
2. Dorian P, Jung W, Newman D, et al. The
impairment of health-related quality of life in
patients with intermittent atrial ﬁbrillation: im-
plications for the assessment of investigational
therapy. J Am Coll Cardiol 2000;36:1303–9.
3. Wang TJ, Larson MG, Levy D, et al. Temporal
relations of atrial ﬁbrillation and congestive heart
failure and their joint inﬂuence on mortality: the
Framingham Heart Study. Circulation 2003;107:
2920–5.
4. Roy D, Talajic M, Nattel S, et al. Rhythm control
versus rate control for atrial ﬁbrillation and heart
failure. N Engl J Med 2008;358:2667–77.
5. Wyse DG, Waldo AL, DiMarco JP, et al.
A comparison of rate control and rhythm control in
patients with atrial ﬁbrillation. N Engl J Med
2002;347:1825–33.
6. Saksena S, Slee A, Waldo AL, et al. Cardio-
vascular outcomes in the AFFIRM Trial (AtrialFibrillation Follow-Up Investigation of Rhythm
Management). An assessment of individual anti-
arrhythmic drug therapies compared with rate
control with propensity score-matched analyses.
J Am Coll Cardiol 2011;58:1975–85.
7. Chugh SS, Havmoeller R, Narayanan K, et al.
Worldwide epidemiology of atrial ﬁbrillation: a
global burden of disease 2010 study. Circulation
2014;129:837–47.
8. Stevenson IH, Teichtahl H, Cunnington D,
Ciavarella S, Gordon I, Kalman JM. Prevalence of
sleep disordered breathing in paroxysmal and per-
sistent atrial ﬁbrillation patients with normal left
ventricular function. Eur Heart J 2008;29:1662–9.
9. Wang TJ, Parise H, Levy D, et al. Obesity and
the risk of new-onset atrial ﬁbrillation. JAMA
2004;292:2471–7.
10. Heeringa J, van der Kuip DA, Hofman A, et al.
Prevalence, incidence and lifetime risk of atrial
ﬁbrillation: the Rotterdam study. Eur Heart J
2006;27:949–53.
11. Lloyd-Jones DM, Wang TJ, Leip EP, et al.
Lifetime risk for development of atrial ﬁbrillation:the Framingham Heart Study. Circulation 2004;
110:1042–6.
12. Bleumink GS, Knetsch AM, Sturkenboom MC,
et al. Quantifying the heart failure epidemic:
prevalence, incidence rate, lifetime risk and
prognosis of heart failure: the Rotterdam Study.
Eur Heart J 2004;25:1614–9.
13. Ho KK, Pinsky JL, Kannel WB, Levy D. The
epidemiology of heart failure: the Framingham
Study. J Am Coll Cardiol 1993;22:6A–13A.
14. Jenkins LS, Brodsky M, Schron E, et al. Quality
of life in atrial ﬁbrillation: the Atrial Fibrillation
Follow-up Investigation of Rhythm Management
(AFFIRM) study. Am Heart J 2005;149:112–20.
15. Suman-Horduna I, Roy D, Frasure-Smith N,
et al. Quality of life and functional capacity in
patients with atrial ﬁbrillation and congestive
heart failure. J Am Coll Cardiol 2013;61:455–60.
16. Schron E, Friedmann E, Thomas SA. Does
health-related quality of life predict hospitaliza-
tion or mortality in patients with atrial ﬁbrillation?
J Cardiovasc Electrophysiol 2014;25:23–8.
J A C C V O L . 6 4 , N O . 7 , 2 0 1 4 Trulock et al.
A U G U S T 1 9 , 2 0 1 4 : 7 1 0 – 2 1 Rhythm Control in AF With HF
71917. Wolf PA, Abbott RD, Kannel WB. Atrial ﬁbril-
lation as an independent risk factor for stroke: the
Framingham Study. Stroke 1991;22:983–8.
18. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke
severity in atrial ﬁbrillation. The Framingham
Study. Stroke 1996;27:1760–4.
19. Sherman DG, Kim SG, Boop BS, et al. Occur-
rence and characteristics of stroke events in the
Atrial Fibrillation Follow-up Investigation of Sinus
Rhythm Management (AFFIRM) study. Arch Intern
Med 2005;165:1185–91.
20. Bunch TJ, May HT, Bair TL, et al. Atrial ﬁbril-
lation ablation patients have long-term stroke
rates similar to patients without atrial ﬁbrillation
regardless of CHADS2 score. Heart Rhythm 2013;
10:1272–7.
21. Themistoclakis S, Corrado A, Marchlinski FE,
et al. The risk of thromboembolism and need for
oral anticoagulation after successful atrial ﬁbril-
lation ablation. J Am Coll Cardiol 2010;55:735–43.
22. Saad EB, d’Avila A, Costa IP, et al. Very low
risk of thromboembolic events in patients un-
dergoing successful catheter ablation of atrial
ﬁbrillation with a CHADS2 score #3: a long-term
outcome study. Circ Arrhythm Electrophysiol
2011;4:615–21.
23. Grace AA, Narayan SM. Common threads in
atrial ﬁbrillation and heart failure. Heart Fail Clin
2013;9:373–83, vii.
24. Chugh SS, Blackshear JL, Shen WK,
Hammill SC, Gersh BJ. Epidemiology and natural
history of atrial ﬁbrillation: clinical implications.
J Am Coll Cardiol 2001;37:371–8.
25. Dries DL, Exner DV, Gersh BJ, Domanski MJ,
Waclawiw MA, Stevenson LW. Atrial ﬁbrillation is
associated with an increased risk for mortality and
heart failure progression in patients with asymp-
tomatic and symptomatic left ventricular systolic
dysfunction: a retrospective analysis of the SOLVD
trials. J Am Coll Cardiol 1998;32:695–703.
26. Naccarelli GV, Varker H, Lin J, Schulman KL.
Increasing prevalence of atrial ﬁbrillation and
ﬂutter in the United States. Am J Cardiol 2009;
104:1534–9.
27. Stevenson WG, Stevenson LW, Middlekauff HR,
et al. Improving survival for patients with atrial
ﬁbrillation and advanced heart failure. J Am Coll
Cardiol 1996;28:1458–63.
28. Khazanie P, Liang L, Qualls LG, et al. Outcomes
of Medicare beneﬁciaries with heart failure and
atrial ﬁbrillation. J Am Coll Cardiol Heart Fail
2014;2:41–8.
29. Kalifa J, Jalife J, Zaitsev AV, et al. Intra-atrial
pressure increases rate and organization of waves
emanating from the superior pulmonary veins
during atrial ﬁbrillation. Circulation 2003;108:
668–71.
30. Lalani GG, Schricker A, Gibson M, Rostamian A,
Krummen DE, Narayan SM. Atrial conduction slows
immediately before the onset of human atrial
ﬁbrillation: a bi-atrial contact mapping study of
transitions to atrial ﬁbrillation. J Am Coll Cardiol
2012;59:595–606.
31. Mills RW, Narayan SM, McCulloch AD. Mecha-
nisms of conduction slowing during myocardial
stretch by ventricular volume loading in therabbit. Am J Physiol Heart Circ Physiol 2008;295:
H1270–8.
32. Stiles MK, John B, Wong CX, et al. Paroxysmal
lone atrial ﬁbrillation is associated with an
abnormal atrial substrate: characterizing the
“second factor.” J Am Coll Cardiol 2009;53:
1182–91.
33. Healey JS, Israel CW, Connolly SJ, et al. Rele-
vance of electrical remodeling in human atrial
ﬁbrillation: results of the Asymptomatic Atrial
Fibrillation and Stroke Evaluation in Pacemaker
Patients and the Atrial Fibrillation Reduction Atrial
Pacing Trial mechanisms of atrial ﬁbrillation study.
Circ Arrhythm Electrophysiol 2012;5:626–31.
34. Li D, Shinagawa K, Pang L, et al. Effects
of angiotensin-converting enzyme inhibition on
the development of the atrial ﬁbrillation sub-
strate in dogs with ventricular tachypacing-
induced congestive heart failure. Circulation
2001;104:2608–14.
35. Markides V, Schilling RJ, Ho SY, Chow AW,
Davies DW, Peters NS. Characterization of left
atrial activation in the intact human heart. Circu-
lation 2003;107:733–9.
36. Narayan SM, Franz MR, Clopton P, Pruvot EJ,
Krummen DE. Repolarization alternans reveals
vulnerability to human atrial ﬁbrillation. Circula-
tion 2011;123:2922–30.
37. Deedwania PC, Lardizabal JA. Atrial ﬁbrillation
in heart failure: a comprehensive review. Am J
Medicine 2010;123:198–204.
38. Clark DM, Plumb VJ, Epstein AE, Kay GN. He-
modynamic effects of an irregular sequence of
ventricular cycle lengths during atrial ﬁbrillation.
J Am Coll Cardiol 1997;30:1039–45.
39. Nerheim P, Birger-Botkin S, Piracha L,
Olshansky B. Heart failure and sudden death in
patients with tachycardia-induced cardiomyopa-
thy and recurrent tachycardia. Circulation 2004;
110:247–52.
40. Raymond RJ, Lee AJ, Messineo FC,
Manning WJ, Silverman DI. Cardiac performance
early after cardioversion from atrial ﬁbrillation.
Am Heart J 1998;136:435–42.
41. Shelton RJ, Clark AL, Goode K, et al.
A randomised, controlled study of rate versus
rhythm control in patients with chronic atrial
ﬁbrillation and heart failure: (CAFE-II Study).
Heart 2009;95:924–30.
42. Fuster V, Ryden LE, Cannom DS, et al. 2011
ACCF/AHA/HRS focused updates incorporated into
the ACC/AHA/ESC 2006 guidelines for the man-
agement of patients with atrial ﬁbrillation: a
report of the American College of Cardiology
Foundation/American Heart Association Task
Force on practice guidelines. J Am Coll Cardiol
2011;57:e101–98.
43. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011
ACCF/AHA/HRS focused update on the manage-
ment of patients with atrial ﬁbrillation (update on
dabigatran): a report of the American College of
Cardiology Foundation/American Heart Associa-
tion Task Force on practice guidelines. J Am Coll
Cardiol 2011;57:1330–7.
44. Singla S, Karam P, Deshmukh AJ, Mehta J,
Paydak H. Review of contemporary antiarrhythmicdrug therapy for maintenance of sinus rhythm in
atrial ﬁbrillation. J Cardiovasc Pharmacol Ther
2012;17:12–20.
45. Roy D, Talajic M, Dorian P, et al., Canadian
Trial of Atrial Fibrillation Investigators. Amiodar-
one to prevent recurrence of atrial ﬁbrillation.
N Engl J Med 2000;342:913–20.
46. Kirchhof P, Breithardt G, Aliot E, et al.
Personalized management of atrial ﬁbrillation:
proceedings from the fourth Atrial Fibrillation
competence NETwork/European Heart Rhythm
Association consensus conference. Europace 2013;
15:1540–56.
47. Scirica BM, Morrow DA, Hod H, et al. Effect of
ranolazine, an antianginal agent with novel elec-
trophysiological properties, on the incidence of
arrhythmias in patients with non ST-segment
elevation acute coronary syndrome: results from
the Metabolic Efﬁciency With Ranolazine for Less
Ischemia in Non ST-Elevation Acute Coronary
Syndrome Thrombolysis in Myocardial Infarction
36 (MERLIN-TIMI 36) randomized controlled trial.
Circulation 2007;116:1647–52.
48. Stone PH. Ranolazine: new paradigm for
management of myocardial ischemia, myocardial
dysfunction, and arrhythmias. Cardiol Clin 2008;
26:603–14.
49. Fragakis N, Koskinas KC, Katritsis DG,
Pagourelias ED, Zografos T, Geleris P. Comparison
of effectiveness of ranolazine plus amiodarone
versus amiodarone alone for conversion of recent-
onset atrial ﬁbrillation. Am J Cardiol 2012;110:
673–7.
50. Koskinas KC, Fragakis N, Katritsis D,
Skeberis V, Vassilikos V. Ranolazine enhances
the efﬁcacy of amiodarone for conversion of
recent-onset atrial ﬁbrillation. Europace 2014;
16:973–9.
51. Milberg P, Frommeyer G, Ghezelbash S, et al.
Sodium channel block by ranolazine in an experi-
mental model of stretch-related atrial ﬁbrillation:
prolongation of interatrial conduction time and
increase in post-repolarization refractoriness.
Europace 2013;15:761–9.
52. Ezekowitz MD, Nagarakanti R, Lubinski A, et al.
A randomized trial of budiodarone in paroxysmal
atrial ﬁbrillation. J Interv Cardiac Electrophysiol
2012;34:1–9.
53. Aleong RG, Sauer WH, Davis G, et al. Preven-
tion of atrial ﬁbrillation by bucindolol is depen-
dent on the beta1389 Arg/Gly adrenergic receptor
polymorphism. J Am Coll Cardiol Heart Fail 2013;1:
338–44.
54. Calkins H. Catheter ablation to maintain sinus
rhythm. Circulation 2012;125:1439–45.
55. Kong MH, Piccini JP, Bahnson TD. Efﬁcacy of
adjunctive ablation of complex fractionated atrial
electrograms and pulmonary vein isolation for the
treatment of atrial ﬁbrillation: a meta-analysis of
randomized controlled trials. Europace 2011;13:
193–204.
56. Shivkumar K, Ellenbogen KA, Hummel JD,
Miller JM, Steinberg JS. Acute termination of hu-
man atrial ﬁbrillation by identiﬁcation and cath-
eter ablation of localized rotors and sources: ﬁrst
multicenter experience of focal impulse and rotor
Trulock et al. J A C C V O L . 6 4 , N O . 7 , 2 0 1 4
Rhythm Control in AF With HF A U G U S T 1 9 , 2 0 1 4 : 7 1 0 – 2 1
720modulation (FIRM) ablation. J Cardiovasc Elec-
trophysiol 2012;23:1277–85.
57. Narayan SM, Krummen DE, Shivkumar K,
Clopton P, Rappel WJ, Miller JM. Treatment of
atrial ﬁbrillation by the ablation of localized
sources: CONFIRM (Conventional Ablation for
Atrial Fibrillation With or Without Focal Impulse
and Rotor Modulation) trial. J Am Coll Cardiol
2012;60:628–36.
58. Calkins H, Kuck KH, Cappato R, et al. 2012
HRS/EHRA/ECAS expert consensus statement on
catheter and surgical ablation of atrial ﬁbrillation:
recommendations for patient selection, procedural
techniques, patient management and follow-up,
deﬁnitions, endpoints, and research trial design.
Europace 2012;14:528–606.
59. Wilber DJ, Pappone C, Neuzil P, et al. Com-
parison of antiarrhythmic drug therapy and radi-
ofrequency catheter ablation in patients with
paroxysmal atrial ﬁbrillation: a randomized
controlled trial. JAMA 2010;303:333–40.
60. Noheria A, Kumar A, Wylie JV Jr.,
Josephson ME. Catheter ablation vs antiar-
rhythmic drug therapy for atrial ﬁbrillation: a
systematic review. Arch Intern Med 2008;168:
581–6.
61. Terasawa T, Balk EM, Chung M, et al. Sys-
tematic review: comparative effectiveness of
radiofrequency catheter ablation for atrial ﬁbril-
lation. Ann Intern Med 2009;151:191–202.
62. Cosedis Nielsen J, Johannessen A,
Raatikainen P, et al. Radiofrequency ablation as
initial therapy in paroxysmal atrial ﬁbrillation.
N Engl J Med 2012;367:1587–95.
63. Wazni OM, Marrouche NF, Martin DO, et al.
Radiofrequency ablation vs antiarrhythmic drugs
as ﬁrst-line treatment of symptomatic atrial
ﬁbrillation: a randomized trial. JAMA 2005;293:
2634–40.
64. Morillo CA, Verma A, Connolly SJ, et al.
Radiofrequency ablation vs antiarrhythmic drugs
as ﬁrst-line treatment of paroxysmal atrial ﬁbril-
lation (RAAFT-2): a randomized trial. JAMA 2014;
311:692–700.
65. Chen MS, Marrouche NF, Khaykin Y, et al.
Pulmonary vein isolation for the treatment of
atrial ﬁbrillation in patients with impaired systolic
function. J Am Coll Cardiol 2004;43:1004–9.
66. Gentlesk PJ, Sauer WH, Gerstenfeld EP, et al.
Reversal of left ventricular dysfunction following
ablation of atrial ﬁbrillation. J Cardiovasc Elec-
trophysiol 2007;18:9–14.
67. Wood MA, Brown-Mahoney C, Kay GN,
Ellenbogen KA. Clinical outcomes after ablation
and pacing therapy for atrial ﬁbrillation: a meta-
analysis. Circulation 2000;101:1138–44.
68. Khan MN, Jais P, Cummings J, et al. Pulmo-
nary-vein isolation for atrial ﬁbrillation in pa-
tients with heart failure. N Engl J Med 2008;359:
1778–85.
69. MacDonald MR, Connelly DT, Hawkins NM,
et al. Radiofrequency ablation for persistent atrial
ﬁbrillation in patients with advanced heart failure
and severe left ventricular systolic dysfunction: a
randomised controlled trial. Heart 2011;97:740–7.70. Hunter RJ, Berriman TJ, Diab I, et al.
A randomised controlled trial of Catheter Ablation
versus Medical Treatment of Atrial Fibrillation in
Heart Failure (the CAMTAF trial). Circ Arrhythm
Electrophysiol 2014;7:31–8.
71. Jones DG, Haldar SK, Hussain W, et al.
A randomized trial to assess catheter ablation
versus rate control in the management of persis-
tent atrial ﬁbrillation in heart failure. J Am Coll
Cardiol 2013;61:1894–903.
72. Machino-Ohtsuka T, Seo Y, Ishizu T, et al. Ef-
ﬁcacy, safety, and outcomes of catheter ablation
of atrial ﬁbrillation in patients with heart failure
with preserved ejection fraction. J Am Coll Cardiol
2013;62:1857–65.
73. Wilton SB, Fundytus A, Ghali WA, et al. Meta-
analysis of the effectiveness and safety of catheter
ablation of atrial ﬁbrillation in patients with versus
without left ventricular systolic dysfunction. Am J
Cardiol 2010;106:1284–91.
74. Faustino M, Pizzi C, Capuzzi D, et al. The
impact of atrial ﬁbrillation termination mode dur-
ing catheter ablation procedure on maintenance of
sinus rhythm. Heart Rhythm 2014 May 24 [E-pub
ahead of print].
75. Park YM, Choi JI, Lim HE, Park SW, Kim YH. Is
pursuit of termination of atrial ﬁbrillation during
catheter ablation of great value in patients with
longstanding persistent atrial ﬁbrillation?
J Cardiovasc Electrophysiol 2012;23:1051–8.
76. O’Neill MD, Wright M, Knecht S, et al. Long-
term follow-up of persistent atrial ﬁbrillation
ablation using termination as a procedural
endpoint. Eur Heart J 2009;30:1105–12.
77. Elayi CS, Di Biase L, Barrett C, et al. Atrial
ﬁbrillation termination as a procedural endpoint
during ablation in long-standing persistent atrial
ﬁbrillation. Heart Rhythm 2010;7:1216–23.
78. Gaita F, Caponi D, Scaglione M, et al. Long-
term clinical results of 2 different ablation stra-
tegies in patients with paroxysmal and persistent
atrial ﬁbrillation. Circ Arrhythm Electrophysiol
2008;1:269–75.
79. Anter E, Tschabrunn CM, Contreras-
Valdes FM, Buxton AE, Josephson ME. Radio-
frequency ablation annotation algorithm reduces
the incidence of linear gaps and reconnection after
pulmonary vein isolation. Heart Rhythm 2014;11:
783–90.
80. Metzner A, Reissmann B, Rausch P, et al.
One-year clinical outcome after pulmonary vein
isolation using the second-generation 28-mm
cryoballoon. Circ Arrhythm Electrophysiol 2014;7:
288–92.
81. Kimura M, Sasaki S, Owada S, et al. Comparison
of lesion formation between contact force-guided
and non-guided circumferential pulmonary vein
isolation: a prospective, randomized study. Heart
Rhythm 2014;11:984–91.
82. Baykaner T, Clopton P, Lalani GG, et al. Tar-
geted ablation at stable atrial ﬁbrillation sources
improves success over conventional ablation in
high-risk patients: a substudy of the CONFIRM
trial. Can J Cardiol 2013;29:1218–26.
83. Gersak B, Pernat A, Robic B, Sinkovec M. Low
rate of atrial ﬁbrillation recurrence veriﬁed byimplantable loop recorder monitoring following a
convergent epicardial and endocardial ablation of
atrial ﬁbrillation. J Cardiovasc Electrophysiol 2012;
23:1059–66.
84. Gersak B, Zembala MO, Muller D, et al. Euro-
pean experience of the convergent atrial ﬁbrilla-
tion procedure: multicenter outcomes in
consecutive patients. J Thorac Cardiovasc Surg
2014;147:1411–6.
85. Gehi AK, Mounsey JP, Pursell I, et al. Hybrid
epicardial-endocardial ablation using a peri-
cardioscopic technique for the treatment of atrial
ﬁbrillation. Heart Rhythm 2013;10:22–8.
86. Kong MH, Lopes RD, Piccini JP, Hasselblad V,
Bahnson TD, Al-Khatib SM. Surgical Maze proce-
dure as a treatment for atrial ﬁbrillation: a
meta-analysis of randomized controlled trials.
Cardiovasc Ther 2010;28:311–26.
87. Al-Khatib SM, Allen LaPointe NM,
Chatterjee R, et al. Rate- and rhythm-control
therapies in patients with atrial ﬁbrillation: a sys-
tematic review. Ann Intern Med 2014;160:760–73.
88. Doty JR, Doty DB, Jones KW, et al. Compari-
son of standard Maze III and radiofrequency Maze
operations for treatment of atrial ﬁbrillation.
J Thorac Cardiovasc Surg 2007;133:1037–44.
89. Stulak JM, Dearani JA, Sundt TM 3rd, et al.
Superiority of cut-and-sew technique for the Cox
maze procedure: comparison with radiofrequency
ablation. J Thorac Cardiovasc Surg 2007;133:
1022–7.
90. Ad N, Henry L, Hunt S. The impact of surgical
ablation in patients with low ejection fraction,
heart failure, and atrial ﬁbrillation. Eur J Car-
diothorac Surg 2011;40:70–6.
91. Gami AS, Hodge DO, Herges RM, et al.
Obstructive sleep apnea, obesity, and the risk of
incident atrial ﬁbrillation. J Am Coll Cardiol 2007;
49:565–71.
92. Chamberlain AM, Agarwal SK, Ambrose M,
Folsom AR, Soliman EZ, Alonso A. Metabolic syn-
drome and incidence of atrial ﬁbrillation among
blacks and whites in the Atherosclerosis Risk in
Communities (ARIC) study. Am Heart J 2010;159:
850–6.
93. Huxley RR, Alonso A, Lopez FL, et al. Type 2
diabetes, glucose homeostasis and incident atrial
ﬁbrillation: the Atherosclerosis Risk in Commu-
nities study. Heart 2012;98:133–8.
94. Alonso A, Lopez FL, Matsushita K, et al.
Chronic kidney disease is associated with the
incidence of atrial ﬁbrillation: the Atherosclerosis
Risk in Communities (ARIC) study. Circulation
2011;123:2946–53.
95. Haider AW, Larson MG, Franklin SS, Levy D,
Framingham Heart Study. Systolic blood pressure,
diastolic blood pressure, and pulse pressure as
predictors of risk for congestive heart failure in the
Framingham Heart Study. Ann Intern Med 2003;
138:10–6.
96. Gopal DM, Kalogeropoulos AP,
Georgiopoulou VV, et al. Cigarette smoking
exposure and heart failure risk in older adults: the
Health, Aging, and Body Composition Study. Am
Heart J 2012;164:236–42.
J A C C V O L . 6 4 , N O . 7 , 2 0 1 4 Trulock et al.
A U G U S T 1 9 , 2 0 1 4 : 7 1 0 – 2 1 Rhythm Control in AF With HF
72197. Fall T, Hagg S, Magi R, et al. The role of adiposity
in cardiometabolic traits: a Mendelian randomization
analysis. PLoS Med 2013;10:e1001474.
98. Pazin-Filho A, Kottgen A, Bertoni AG, et al.
HbA1c as a risk factor for heart failure in persons
with diabetes: the Atherosclerosis Risk in Com-
munities (ARIC) study. Diabetologia 2008;51:
2197–204.
99. Kottgen A, Russell SD, Loehr LR, et al. Reduced
kidney function as a risk factor for incident heart
failure: the Atherosclerosis Risk in Communities
(ARIC) study. J Am Soc Nephrol 2007;18:1307–15.
100. Gottlieb DJ, Yenokyan G, Newman AB, et al.
Prospective study of obstructive sleep apnea and
incident coronary heart disease and heart failure:
the Sleep Heart Health Study. Circulation 2010;
122:352–60.
101. Levy D, Larson MG, Vasan RS, Kannel WB,
Ho KK. The progression from hypertension to
congestive heart failure. JAMA 1996;275:1557–62.102. Bardy GH, Lee KL, Mark DB, et al. Amiodar-
one or an implantable cardioverter-deﬁbrillator
for congestive heart failure. N Engl J Med 2005;
352:225–37.
103. Kadish A, Dyer A, Daubert JP, et al. Prophy-
lactic deﬁbrillator implantation in patients with
nonischemic dilated cardiomyopathy. N Engl J
Med 2004;350:2151–8.
104. McMurray JJ, Ostergren J, Swedberg K, et al.
Effects of candesartan in patients with chronic
heart failure and reduced left-ventricular systolic
function taking angiotensin-converting-enzyme
inhibitors: the CHARM-Added trial. Lancet 2003;
362:767–71.
105. Massie BM, Carson PE, McMurray JJ, et al.
Irbesartan in patients with heart failure and pre-
served ejection fraction. N Engl J Med 2008;359:
2456–67.
106. Taylor AL, Ziesche S, Yancy C, et al. Combi-
nation of isosorbide dinitrate and hydralazine inblacks with heart failure. N Engl J Med 2004;351:
2049–57.
107. Zannad F, McMurray JJ, Krum H, et al.
Eplerenone in patients with systolic heart fail-
ure and mild symptoms. N Engl J Med 2011;364:
11–21.
108. Kober L, Torp-Pedersen C, McMurray JJ,
et al. Increased mortality after dronedarone ther-
apy for severe heart failure. N Engl J Med 2008;
358:2678–87.
109. The CONSENSUS Trial Study Group. Effects
of enalapril on mortality in severe conges-
tive heart failure. Results of the Cooperative
North Scandinavian Enalapril Survival Study
(CONSENSUS). N Engl J Med 1987;316:1429–35.KEY WORDS antiarrhythmic drug therapy,
atrial ﬁbrillation, catheter ablation,
heart failure, rhythm control
